Cerenome (CNSY) vs Intelligent Bio Solutions (INBS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cerenome is the larger company by market cap ($6.2 million vs $4.6 million), about 1.3 times the size, while Intelligent Bio Solutions is growing revenue faster (+38.1% vs -10.5%). Intelligent Bio Solutions converts more of its revenue into profit, with a net margin of -294.9% versus -429.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNSY | INBS |
|---|---|---|
| Share price | $0.6301 | $1.39 |
| Market cap | $6.16M | $4.61M |
| 1-day change | -10.29% | -7.95% |
| YTD return | -95.06% | — |
| 1-year return | -95.24% | — |
| 5-year return | -99.89% | — |
| Forward P/E | — | 3.97 |
| EPS (TTM) | $-3.50 | $-6.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.21M | $4.22M |
| Revenue growth (YoY) | -10.49% | +38.09% |
| Net income (latest FY) | $-22.39M | $-12.43M |
| Gross margin | — | 48.63% |
| Operating margin | -293.46% | -299.11% |
| Net margin | -429.43% | -294.91% |
| 52-week high | $19.00 | $24.90 |
| 52-week low | $0.43 | $1.35 |
| Distance from 52-week high | -96.68% | -94.42% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +4304.06% | +763.31% |
| Average volume | 804.18K | 129.01K |
| Shares outstanding | 9.78M | 3.32M |
| Employees | 28 | 59 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Intelligent Bio Solutions is more profitable, keeping -294.9 cents of every revenue dollar as net income versus -429.4 cents for Cerenome.
- Intelligent Bio Solutions grew revenue faster in its latest fiscal year (+38.09% vs -10.49%).
About Cerenome
CNSY stock →Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Health Care · Medical/Dental Instruments · 28 employees
About Intelligent Bio Solutions
INBS stock →Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform.
Health Care · Medical/Dental Instruments · 59 employees
CNSY vs INBS FAQ
Which is bigger, Cerenome or Intelligent Bio Solutions?
Cerenome (CNSY) is larger, with a market capitalization of $6.16M compared with $4.61M for Intelligent Bio Solutions (INBS).
Are Cerenome and Intelligent Bio Solutions in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.